Log in
Enquire now
Forbion Capital Partners

Forbion Capital Partners

Dutch venture capital firm investing on companies in the life sciences industry.

OverviewStructured DataIssuesContributors
Is a
Venture capital firm
Venture capital firm
Company
Company
Investor
Investor
Organization
Organization
AngelList URL
angel.co/forbion-ca...al-partners
B2X
B2B
B2B
Company Operating Status
Active
Country
Singapore
Singapore
0
Germany
Germany
0
Netherlands
Netherlands
0
Crunchbase URL
crunchbase.com/organiz...partners
Email Address
info@forbion.com
0
Founded Date
2000
0
Founder
Sander Slootweg
Sander Slootweg
0
Full Address
Gärtnerplatz 6 80469 München Germany
0
Gooimeer 2-35, Naarden, NL
0
PO Box 5187 1410 AD Naarden The Netherlands
0
Industry
Biotechnology
Biotechnology
Technology
Technology
Biology
Biology
Invested in
NeRRe Therapeutics
NeRRe Therapeutics
Inversago Pharma
Inversago Pharma
Dyne Therapeutics
Dyne Therapeutics
Mitralign
Mitralign
‌
Amakem
NewAmsterdam Pharma
NewAmsterdam Pharma
BioVex
BioVex
Rigontec GmbH
Rigontec GmbH
Replimune Group
Replimune Group
Curetis (company)
Curetis (company)
•••
LinkedIn URL
@company/forbion-capital-partners
Location
Singapore
Singapore
0
Münchenbernsdorf
Münchenbernsdorf
0
Naarden
Naarden
0
Number of Employees (Ranges)
11 – 50
0
Phone Number
+6587532994
0
+31356993000
0
+4989416161950
0
Twitter URL
@ForbionLifeSci
Official Website
forbion.com/en/
Wellfound ID
forbion-capital-partners

Find more companies like Forbion Capital Partners

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.